文献速递心脏核医学

124I-evuzamitide PET/CT评估罕见类型淀粉样变心脏受累

Assessment of cardiac involvement in rare forms of amyloidosis using positron emission tomography/computed tomography with 124I-evuzamitide (124I-p5+14, AT-01).
PubMed 文献 · J Nucl Cardiol · 2026-04-02

本研究纳入10例罕见类型淀粉样变患者(6例伴心肌病、4例不伴心肌病)和12名对照,注射124I-evuzamitide后5小时行PET/CT。所有伴心肌病的淀粉样变患者均可见心肌摄取,对照组无心肌摄取;不伴心肌病的4例中3例虽有心肌摄取但超声、磁共振和/或SPECT未见淀粉样变征象。LV %ID可区分各组(P=0.002)。

要点

  • 124I-evuzamitide PET/CT可检测罕见类型淀粉样变的心脏受累。
  • 伴心肌病的淀粉样变患者均可见心肌摄取,对照组均无心肌摄取。
  • 部分不伴心肌病者虽有心肌摄取,但其他影像学检查阴性。

核心结论

  • 124I-evuzamitide PET/CT有望无创诊断罕见类型淀粉样变的心脏受累,并可能在其他影像学检查阴性时检出心肌病。

研究设计与样本

  • 研究纳入10例罕见类型淀粉样变患者(6例伴心肌病、4例不伴心肌病)和12名对照,注射124I-evuzamitide后5小时行PET/CT,中位净注射活度为0.97 mCi。

主要发现

  • 所有伴心肌病的淀粉样变患者均可见心肌放射性摄取,而对照组均无心肌摄取。
  • 不伴心肌病的4例淀粉样变患者中3例可见心肌摄取,尽管超声、磁共振和/或SPECT未见淀粉样变征象。
  • 孤立性肺AL淀粉样变患者心肌摄取正常。
  • LV %ID可区分各组(P=0.002):伴心肌病组中位数1.74(范围0.20-2.53),不伴心肌病组0.22(0.00-1.16),对照组0.00(0.00-0.02)。

临床怎么用

  • 对于罕见类型淀粉样变患者,可考虑使用124I-evuzamitide PET/CT评估心脏受累,尤其在其他影像学检查阴性时。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: 124I-evuzamitide (124I-p5+14, AT-01) is a novel pan-amyloid-binding radiotracer that accurately detects cardiomyopathy in light chain and wild-type transthyretin amyloidosis. However, data on this radiotracer are limited in rarer forms of amyloidosis, for which diagnosing cardiac involvement can be challenging. Hence, we investigated the ability of 124I-evuzamitide positron emission tomography/computed tomography (PET/CT) to detect cardiac involvement in rare forms of amyloidosis with or without known cardiomyopathy. METHODS AND RESULTS: We enrolled 10 participants with rare amyloidosis: 6 with cardiomyopathy (2 ATTRv p.T80A, ATTRv p.V142I, ATTRv p.L78H, AApoAIV, and AGel + ATTRwt) and 4 without cardiomyopathy (ATTRv p.G107R, 2 AApoAI, and localized pulmonary AL), and 12 control participants. They underwent PET/CT 5 hours after 124I-evuzamitide injection (median net injected activity: 0.97 mCi). Images were assessed visually, then myocardial radiotracer uptake above the blood pool was quantified using multiple metrics, including left ventricular percent injected dose (LV %ID = [LV mean activity concentration/injected activity] x LV activity volume x 100). All amyloidosis participants with cardiomyopathy exhibited visible myocardial uptake, while control participants showed no myocardial uptake. Among amyloidosis participants without cardiomyopathy, 3/4 exhibited myocardial uptake despite no signs of amyloidosis on echocardiogram, magnetic resonance imaging, and/or single-photon emission computed tomography. The participant with localized pulmonary AL showed normal myocardial uptake. LV %ID appropriately discriminated groups (P = 0.002): cardiomyopathy median: 1.74 (range: 0.20-2.53), no cardiomyopathy: 0.22 (0.00-1.16), control: 0.00 (0.00-0.02). CONCLUSIONS: 124I-evuzamitide PET/CT offers the potential to noninvasively diagnose cardiac involvement in rare forms of amyloidosis and may detect cardiomyopathy when other imaging methods are negative.

来源:J Nucl Cardiol,查看原文。版权归原作者所有。

引用

  1. Clerc OF, Romero Pabón AJ, Cuddy SAM, et al. Assessment of cardiac involvement in rare forms of amyloidosis using positron emission tomography/computed tomography with 124I-evuzamitide (124I-p5+14, AT-01). J Nucl Cardiol. 2026. PMID: 41935606. doi:10.1016/j.nuclcard.2026.102707

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。